Simcere Pharmaceuticals and Idorsia announced that they have entered into a licensing agreement in China for Idorsia's daridorexant, an orexin antagonist medication used for the treatment of insomnia.
Five cannabinoid products that all contained cannabidiol (CBD) were compared against a control product containing 5 mg of melatonin only.
Apnimed’s AD109 has the potential to be the first oral pharmacologic that treats OSA airway obstruction at night.
'The Sunosi acquisition marks the transformation of Axsome into a commercial neuroscience company and reflects our commitment to the millions of people living with serious neurologic and psychiatric conditions.'
In a small study of healthy adults aged 55 and older, 5 mg of melatonin increased total sleep time compared to a placebo.
Incannex characterized the pre-investigational new drug application (pre-IND) meeting about IHL-42X as “highly constructive.”